Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

1.

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP.

Cancer. 2009 Sep 15;115(18):4136-47. doi: 10.1002/cncr.24504.

PMID:
19536906
[PubMed - indexed for MEDLINE]
Free Article
2.

Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.

Abbott BL.

Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27. Review.

PMID:
22285209
[PubMed - indexed for MEDLINE]
3.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.

Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Review.

PMID:
23134589
[PubMed - indexed for MEDLINE]
Free Article
4.
5.

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K.

Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220. Review.

PMID:
22551803
[PubMed - indexed for MEDLINE]
Free Article
6.

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.

Kantarjian HM, Cortes J, La Rosée P, Hochhaus A.

Cancer. 2010 Mar 15;116(6):1419-30. doi: 10.1002/cncr.24928. Review.

PMID:
20120030
[PubMed - indexed for MEDLINE]
Free Article
7.

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

McCormack PL, Keam SJ.

Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000. Review.

PMID:
21902298
[PubMed - indexed for MEDLINE]
8.

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Keam SJ.

BioDrugs. 2008;22(1):59-69. Review.

PMID:
18215092
[PubMed - indexed for MEDLINE]
9.

Targeted chronic myeloid leukemia therapy: Seeking a cure.

Fausel C.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. Review.

PMID:
18056932
[PubMed - indexed for MEDLINE]
10.

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.

Hochhaus A.

Expert Opin Pharmacother. 2007 Dec;8(18):3257-64. Review.

PMID:
18035968
[PubMed - indexed for MEDLINE]
11.

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.

Breccia M, Alimena G.

BioDrugs. 2011 Jun 1;25(3):147-57. doi: 10.2165/11591840-000000000-00000. Review.

PMID:
21528941
[PubMed - indexed for MEDLINE]
12.

New approved dasatinib regimen available for clinical use.

Snyder DS.

Expert Rev Anticancer Ther. 2009 Mar;9(3):285-92. doi: 10.1586/14737140.9.3.285. Review.

PMID:
19275507
[PubMed - indexed for MEDLINE]
13.

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.

Loveman E, Cooper K, Bryant J, Colquitt JL, Frampton GK, Clegg A.

Health Technol Assess. 2012;16(23):iii-xiii, 1-137. doi: 10.3310/hta16230. Review.

PMID:
22564553
[PubMed - indexed for MEDLINE]
Free Article
14.

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Stein B, Smith BD.

Clin Ther. 2010 May;32(5):804-20. doi: 10.1016/j.clinthera.2010.05.003. Review.

PMID:
20685492
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Jabbour E, Lipton JH.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):646-56. doi: 10.1016/j.clml.2013.05.012. Epub 2013 Oct 1. Review.

PMID:
24095296
[PubMed - indexed for MEDLINE]
16.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

Wei G, Rafiyath S, Liu D.

J Hematol Oncol. 2010 Nov 26;3:47. doi: 10.1186/1756-8722-3-47. Review.

PMID:
21108851
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.

Tyler T.

Ann Pharmacother. 2009 May;43(5):920-7. doi: 10.1345/aph.1L570. Epub 2009 Mar 31. Review.

PMID:
19336654
[PubMed - indexed for MEDLINE]
18.

Dasatinib: is it all in the dose?

Condorelli F, Genazzani AA.

BioDrugs. 2010 Jun;24(3):157-63. doi: 10.2165/11535870-000000000-00000. Review.

PMID:
20222756
[PubMed - indexed for MEDLINE]
19.

High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.

Gafter-Gvili A, Leader A, Gurion R, Vidal L, Ram R, Shacham-Abulafia A, Ben-Bassat I, Lishner M, Shpilberg O, Raanani P.

Am J Hematol. 2011 Aug;86(8):657-62. doi: 10.1002/ajh.22076. Review.

PMID:
21761431
[PubMed - indexed for MEDLINE]
20.

New strategies in controlling drug resistance in chronic myeloid leukemia.

Frame D.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21. Review.

PMID:
18056927
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk